MOVEMENT DISORDERS CLINICAL PRACTICE
DOI:10.1002/mdc3.12145
DOI:10.1002/mdc3.12145
Autoren:
Santiago Perez-Lloret, MD, PhD, 1,2,*
Olivier Flabeau, MD, 3
Pierre-Olivier Fernagut, PhD, 4,5
Anne Pavy-Le Traon, MD, PhD, 6,7
Maria Veronica Rey, 1,2
Alexandra Foubert-Samier, MD, PhD, 4,5,8
Francois Tison, MD, PhD, 4,5,8
Autoren-Details:
1 Laboratory of Epidemiology and Experimental Pharmacology, Institute for Biomedical Research (BIOMED), School of Medical Sciences, PontificalCatholic University of Argentina (UCA), Buenos Aires, Argentina;
2 The National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina;
3 Department of Neurology, Center Hospitalier de la Cote Basque, Bayonne, France;
4 Institut des Maladies Neuroegeneratives, Universite de Bordeaux, Bordeaux, France;
5 CNRS, Institut des Maladies Neurodegeneratives, Bordeaux, France;
6 Departments of Clinical Pharmacology and Neurosciences, University Hospital and University of Toulouse 3, Toulouse, France;
7 French Reference Center for MSA, Toulouse University Hospital, Toulouse, France;
8 French Reference Center for MSA, Bordeaux University Hospital, Bordeaux, France